期刊文献+

炎症相关细胞因子在弥漫大B细胞淋巴瘤中作用的研究进展 被引量:3

Research progress of role of inflammation related cytokines in diffuse large B-cell lymphoma
下载PDF
导出
摘要 【指示性摘要】IL-6由肿瘤细胞自分泌,与肿瘤侵袭性密切相关;TNF-α在机体肿瘤免疫应答中起到了重要作用,可引起肿瘤细胞坏死,且可诱导IL-6的表达;IFN-γ具有抗病毒,抗肿瘤和免疫调控的作用;IL-10具有双向免疫调节作用,在肿瘤环境中对免疫应答具有负向调节作用,同时也能发挥刺激作用。上述细胞因子在弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)的发生发展中或起到协同作用,并可能作为DLBCL诊断及预后的指标。 IL-6 is autocrine by tumor cells and is closely related to tumor invasion.TNF-αplays an important role in tumor immune response,which can cause tumor cell necrosis and induce IL-6 expression.IFN-γhas anti-virus,anti-tumor and immune regulation.IL-10 has a two-way immunomodulatory effect,which has a negative regulatory effect on the immune response in the tumor environment,and can also exert a stimulating effect.The above cytokines may play a synergistic role in the development of diffuse large B cell lymphoma(DLBCL)and may serve as an indicator for the diagnosis and prognosis of DLBCL.
作者 包雪娇 王树叶 Bao Xuejiao;Wang Shuye(Department of Hematology,First Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150001,China)
出处 《现代肿瘤医学》 CAS 2020年第12期2141-2145,共5页 Journal of Modern Oncology
基金 国家重点基础研究发展计划子课题(编号:2012CBA01303)。
关键词 弥漫大B细胞淋巴瘤 白细胞介素-6 肿瘤坏死因子-α 干扰素-Γ 白细胞介素-10 肿瘤微环境 diffuse large B-cell lymphoma interleukin-6 tumor necrosis factor-α interferon-γ interleukin-10 tumor microenvironment
  • 相关文献

参考文献2

二级参考文献24

  • 1Sehn LH, Gascoyne RE). Diffuse large B--cell lymphoma: optimiz- hag outcome in the context of clinical and biologic heterogeneity [J].Blood, 2015, 125(1):22-32. 被引量:1
  • 2Piris MA. I. Pathological and clinical diversity ha diffuse large B- cell lymphoma[J]. Hematol Oncol, 2013, 31( Suppl 1):23-25. 被引量:1
  • 3A predictive modal for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Fac- tors Project[J]. N EnglJ Med, 1993, 329(14):987--994. 被引量:1
  • 4Coiffier B, Thieblemont C, Van Den Neste E, et al. Long--term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemo- therapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte[J].Blood, 2010, 116(12):2040-2045. 被引量:1
  • 5Ziepert M, Hasendever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for pa- tients with aggressive CD20+ B-cell lymphoma in the rituximab era[J]. Clin Oncol, 2010, 28(14):2373-2380. 被引量:1
  • 6Zhou Z, Sehn LI-'I, Rademaker AW, et al. An enhanced Interna- tional Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era[J]. Blood, 2014, 123(6):837-842. 被引量:1
  • 7Hans CP, Weisenhurger DD, Grehaer TC, et al. Confn'mafion of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray[J]. Blood, 2004, 103(1):275-282. 被引量:1
  • 8Cheson BD, Pfistner B, Juweid ME, et al. Revised response crite- ria for malignant lymphoma[J].Clin Oncol, 2007,25(5):579-586. 被引量:1
  • 9Ngo L, I-Iee SW, Lim LC, et al. Prognostic factors in patients with diffuse large B cell tymphoma: Before and after the introduc- tion of rimximab[J]. Leuk Lymphoma, 2008, 49(3):462-469. 被引量:1
  • 10Sehn LH, Berry B, Chhanabhai M, et al. The revised Internation- al Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-ceU lymphoma treated with R--CHOP[J].Blood, 2007, 109(5):1857-1861. 被引量:1

共引文献13

同被引文献46

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部